Sutro Biopharma is a clinical-stage biotechnology company that develops novel cancer therapies. The company was founded in 2003 and is based in South San Francisco, California. Sutro's proprietary technology platform allows for the rapid design and production of protein therapeutics, which can be used to target specific cancer cells. The company's lead product candidate, STRO-001, is a potential treatment for multiple myeloma and other B-cell malignancies. Sutro has partnerships with several pharmaceutical companies, including Merck and Celgene, to develop and commercialize its products. In 2018, Sutro went public on the NASDAQ stock exchange.